Thrombosis restriction for JAK inhibitor in ulcerative colitis
By Sunalie Silva
7 Aug 2019
The US Food and Drug Administration has restricted the use of high-dose tofacitinib (Xeljanz) in ulcerative colitis and added a black box warning to the label after researchers found a link between the 10 mg dose and a higher risk of pulmonary embolism (PE) and death in patients with rheumatoid arthritis (RA). In a safety ...